Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Jasbir Seehra is CHIEF EXECUTIVE OFFICER at Keros Therapeutics. OQRO lists 6 transactions filed with the SEC under this name, the latest on Apr 6, 2026, each linked to the official Form 4.
CHIEF EXECUTIVE OFFICER
Disclosures on record
6
Companies involved
1
Keros TherapeuticsKROS
6 disclosures · Jan 2026 – Apr 2026 · 1 sold
Apr 2, 202655Kdisclosed Apr 6
DetailsOfficial recordApr 2, 202655Kdisclosed Apr 6
DetailsOfficial recordFeb 24, 2026217Kdisclosed Feb 26
DetailsOfficial recordFeb 24, 2026100Kdisclosed Feb 26
DetailsOfficial recordFeb 19, 2026Sold~$113Kdisclosed Feb 20
DetailsOfficial recordJan 7, 202663Kdisclosed Jan 9
DetailsOfficial recordJasbir Seehra bought shares on the open market in 2020, and has not bought since 2020. Sales in 1 of the 7 years since 2020.
Jasbir Seehra reported 1 open-market purchase and 1 sale since 2020; purchases in 2020.
| Year | Bought | Sold |
|---|---|---|
| 2026 | — | $113K1×1 trade |
| 2020 | $320K1×1 trade | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
As of the latest filing on , Jasbir Seehra reported holding 440,708 shares of Keros Therapeutics (KROS), worth about $4.54M at the last close of $10 (Nov 13, 2026). In the last 12 months, Jasbir Seehra sold $113K in 1 sale.
Keros Therapeutics's proxy statement reports total compensation of $2.54M for Jasbir Seehra for fiscal year 2025. The total is the one in the Summary Compensation Table: it counts stock awards at their value on the grant date, so it is not the cash received. Proxy statement filed Apr 22, 2026
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Keros Therapeutics KROS | 440,708 | 441K direct | $10 | $4.54M | Apr 2, 2026 |
Is this Jasbir Seehra’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
On the latest SEC Form 4, dated Apr 2, 2026, Jasbir Seehra reported holding 440,708 shares of Keros Therapeutics (KROS). At the last close of $10 on Nov 13, 2026, that is about $4.54M. This is the stake disclosed in filings, not a net worth.
In SEC filings of the last 12 months, Jasbir Seehra reported 1 open-market sale worth $113K, and no open-market purchase. Shares withheld for taxes, gifts and option exercises are not counted in these totals.
Keros Therapeutics's proxy statement reports total compensation of $2.54M for Jasbir Seehra for fiscal year 2025. The total is the one in the Summary Compensation Table: it counts stock awards at their value on the grant date, so it is not the cash received.
Jasbir Seehra bought shares on the open market in 2020, and has not bought since 2020. Sales in 1 of the 7 years since 2020.
In SEC filings since 2020: the latest open-market purchase is from 2020; the latest open-market sale is from 2026.
Keros Therapeutics (KROS), from 2020 to 2026: 1 purchase and 1 sale.
Jasbir Seehra reported 1 open-market purchase and 1 sale here, 2020 to 2026.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
